Oxford BioMedica Live Discussion

Live Discuss Polls Ratings Documents
Page

handoverfist 31 May 2018

Re: Price Drop AegeanThank you yet again for your report on the AGm and the conversations you had with some of OXB staff.The link you gave [link] is a very interesting article and well worth reading. I, like most long term OXB holders, are a little disappointed that we no longer expect to be part of a major breakthrough with drugs like Traovax and Metxia but now are part of the support system for companies that will use our lentivector technology until something better or cheaper comes along. We'll hitch our wagon to these runaway super performers and enjoy the ride as long as it lasts.I like the optimism in your postings but don't altogether share it.

cafestock 31 May 2018

Re: Price Drop Are you for real?You dont think very expensive advisors were behind this?Decision making capability... I despair at comments like this. You are very welcome to your opionin, but really????Forgive me if I appear rude and I do not want to engage in a slanging match. Maybe I just read you wrong. Respectfully.

aegian 31 May 2018

Re: Price Drop As the AGM was breaking up I asked JD what he saw as a suitable multiple of today's OXB share price to hope for. He was guarded but did say that the ambition of OXB was to reach a capitalisdation of half a billion pounds.That seems modest. At its turn of the century peak OXB, a penny share, traded at £1.20! Consolidated that would have been about £60 a share. I want OXB to double or even triple in value. Cures for Parkinson's palsy and four different causes of blindness ought to enrich OXB considerably if just one or two of them work. TroVax was evaluated as a potential loser and money pit but OXB can do more innovative research and discover new applications for their Lentivector once they are making money. Up till now they've had to concentrate on the Lentivector istelf, partnerships and financial survival. It is beginning to look as though the board believe financial survival to be virtually assured and the next scale up of Lentivector production seems to be under way. They consolidated because they wanted to cut out wild swings and volatility. As a penny share we were not being taken seriously but were a trading share for nerdy millenials who did not understand anything about the technology. At £7 we can expect it to have a smaller spread and lower volatility.There were quite a few new share holders at the AGM, two from China and one from the USA. They had heard of OXB as being an exciting cutting edge company and they put their money in it. None of them seemed unhappy with what was said at the AGM. I asked the Chinese gentleman why he was interested in OXB. He said, "China is a vast country."The comments and the buzz of interested conversation afterwards was something totally new. Previously a few shareholders would huddle together trying to console ourselves and nerving ourselves to hold on. The new shareholders would not be able to imagine that miserable scene from the past. We have come a long way. Now that there is one girl who is still alive when she might have been dead, there is surely more good news to come: [link] means be cynical about the Board but you risk not being onboard for a genuine ride into the future by British science.

optimistic john 31 May 2018

Re: Price Drop Agreed. This consolidation decision worries me. Why 50-1? Who advised them that 50 was the right number?There must be some reasoning behind this that we don't know about. It makes me question their decision making capability/capacity to run the company effectively.

sandpmag 31 May 2018

Re: Price Drop Yes 1:50 was bonkers. It shouldn't be too long before we hit the £10 mark and they will be looking at a share split!

green.as1953 31 May 2018

Recover. We shall have to wait and see. IMHO it will recover bwtfdik.

Kestrel205 30 May 2018

Re: It wonÂ’t recover Love it when a plan comes together....nice 46p drop today

S17 30 May 2018

Re: It wonÂ’t recover Well Baldrick, that was a good plan. Not. But the fundamentals are the same today as a few months ago, only we aren't dealing in penny shares any more.Back to the trenches lads and dig in for a few more years of waiting. It will all come out right one day as long as we keep looking up. While there's life there's hope. After 20 years of waiting a few more years won't be too hard to bear.

Roger Baron 30 May 2018

Re: Drop Happy to have bought some more!

mala17 30 May 2018

It wonÂ’t recover Seen it happen before when OXB consolidated and after the event it was shorted all the way back to penny’s.

highsnlows 30 May 2018

Price Drop We were told one of the main reasons for the consolidation was to reduce volatility, yeah that worked well didn't it.Today we've had some enormous spreads, far more volatile trading than previously and as if to stick the boot in to us private investors the price has sunk dramatically.1 for 50 was a ridiculous consolidation and never should have been voted through. 1 for 20 was far more reasonable.Any guesses on how long this will take to recover? HnL.

Kestrel205 30 May 2018

Drop Nice share price drop today

aegian 30 May 2018

Re: Profits, what profits? The chart we were shown indicated that OXB had borrowed money every year till last year, when they seem to have generated a £1m cash surplus over operating expenses, rather than borrowing. This seems to show that the company is profitable, if the debts are ignored and will be once they are paid.OXB is at last selling the Lentivector itself to Big Pharma companies who have their own uses for it. One of these products is proving successful enough for the FDA to license it. After that, Lentivector sales are assured. OXB is now a leading supplier, having beaten their own self diagnosed purity and volume production problems and secured the required plant and premises. They are now ready to do profitiable business on that basis, even though TroVax[R] is effectively dead. This seems a shame, as that was the great idea that the Kingsmans had started with, last century. But ProSavin[R] is still promising.Gene Therapeutics is maturing and OXB is maturing along with it. With about 30% of the Lentivector marked, if I heard corrwectly, OXB is well poised to take advantage. People objected when the Kingsmans took profits to reward themselves for starting this company before they died. I didn't get the impression that anyone was in a hurry to do that now, when the shares have been consolidated and appear to be growing in value.

d gaser 30 May 2018

Re: £7.50 per share after 50-1 con... Hi Aegian thanks for taking the time the time to report back to us all ,on the AGM ,it's very much appreciated .It sound to me that they are not doing a cash call per say ,but will be doing a 5% funding operation via institutions as you say .That cash will then be spent on either more plant ,staff, or an acquisition, but talk of an acquisition now seems a bit premature to me ,unless of course they have to do one in order to obtain the space they require in Oxford ,or to buy a specialist storage facility company in the USA . How ever ,that would not of been possible had they not consolidated, and I think we all know that now ,and confirms my thoughts in my last post but thanks for confirming it .You said in your report that the company was now profitable, yet in their finnancial end of year statement they said it would take time before the company became profitable ,what made the differance ? And did any body ask ,if our main stockholder was about to sell down ,and if so ,did you get an answer ?I'm pleased to see a more progressive OXB emerging from all the problems of the past ,and hopefully it will continu to grow in the future . .Thanks for your time Aegian it's much appreciated BE HAPPYDAVE

raptor66 30 May 2018

Re: £7.50 per share after 50-1 consoli... I agree with you dg, the following were my thoughts when consolidation came to light:'Perhaps OXB wants to list on Nasdaq if not already,and possibly raise more money??'

Page